Dyne Therapeutics (NASDAQ:DYN) Given New $17.00 Price Target at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) had its target price decreased by JPMorgan Chase & Co. from $18.00 to $17.00 in a report issued on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. BMO Capital Markets started coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird started coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. Finally, Piper Sandler lowered their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Price Performance

DYN stock opened at $12.08 on Friday. The company has a market cap of $1.37 billion, a P/E ratio of -3.39 and a beta of 1.11. Dyne Therapeutics has a 1 year low of $11.18 and a 1 year high of $47.45. The stock’s fifty day moving average price is $13.60 and its 200-day moving average price is $24.26.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after acquiring an additional 698 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after acquiring an additional 721 shares during the last quarter. KBC Group NV increased its stake in Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares during the last quarter. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the third quarter worth approximately $34,000. Finally, Virtue Capital Management LLC increased its stake in Dyne Therapeutics by 4.4% during the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock worth $834,000 after acquiring an additional 981 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.